Phase II trial of 4'-epi-doxorubicin in patients with advanced malignant melanoma

Thirty-five patients with advanced malignant melanoma were treated with 4'-epi-doxorubicin iv once every 3 weeks. Most patients had not received prior chemotherapy and had good performance status. Three partial remissions and three minor regressions were observed. All patients experienced myelosuppression, but other toxic effects were minimal. 4'-Epi-doxorubicin has limited therapeutic activity in this disease.